The Division of Molecular Virology and Immunology, Georgetown University, supported the NIAID intramural and contract-sponsored extramural programs requiring the expertise and equipment of the NIAID special support laboratory at 5640 Fishers Lane, Rockville, Maryland under contract N01-AI-72623. Additional work was conducted outside the Rockville facility on-campus, at Georgetown, to support the NIAID intramural studies of the virology of the causative agent of AIDS (i.e., the isolation of virus from clinical specimens, purification and characterization of antigens, modification and development of assays for virus and antibodies to the virus). In addition to AIDS virus, the research efforts center on hepadna viruses, hepatitis delta virus; a hepatitis testing laboratory is provided; an electron microscope facility for collaborative studies on membrane receptors in neutrophil activation leading to chemotaxis and/or degranulation; and, mast cell aberrations in a variety of conditions associated with physiologic or pathologic mastocytoses. This contract (N01-AI-05058) was administratively split from N01-AI-72623 to support the work being done in support of DIR and AIDS research.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
United States
Zip Code
Kovacs, J A; Baseler, M; Dewar, R J et al. (1995) Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 332:567-75
Vasudevachari, M B; Salzman, N P; Woll, D R et al. (1993) Clinical utility of an enhanced human immunodeficiency virus type 1 p24 antigen capture assay. J Clin Immunol 13:185-92
Dewar, R L; Sarmiento, M D; Lawton, E S et al. (1992) Isolation of HIV-1 from plasma of infected individuals: an analysis of experimental conditions affecting successful virus propagation. J Acquir Immune Defic Syndr 5:822-8
Vasudevachari, M B; Uffelman, K W; Kovacs, J et al. (1992) Envelope-specific antibodies in the saliva of individuals vaccinated with recombinant HIV-1 gp160. J Acquir Immune Defic Syndr 5:817-21